Skip to main content
. 2016 Oct 14;4(4):E605–E614. doi: 10.9778/cmajo.20160008

Table 5: Key eligibility criteria for reimbursement of paritaprevir-ritonavir-ombitasvir plus dasabuvir (with or without ribavirin) for treatment of hepatitis C virus infection, by jurisdiction.

Jurisdiction Restriction
Minimum fibrosis stage required Substance use HIV coinfection Prescriber Decompensated cirrhosis
Province/territory
British Columbia F2 None listed* Eligible General practitioner None listed
Alberta F2 None listed Eligible General practitioner Ineligible
Saskatchewan F2 None listed† Eligible General practitioner Ineligible
Manitoba F2 None listed Eligible Specialist Ineligible
Ontario F2 None listed Eligible General practitioner Ineligible
Quebec F3‡ None listed Eligible§ General practitioner Ineligible
New Brunswick F2 None listed Eligible General practitioner Ineligible
Nova Scotia F2 None listed Eligible Specialist Ineligible
Prince Edward Island No restrictions None listed¶ Eligible** General practitioner None listed
Newfoundland and Labrador F2 None listed Eligible General practitioner Ineligible
Yukon F2 None listed Eligible Specialist Ineligible
Northwest Territories F2 None listed None listed None listed None listed
Nunavut F2 None listed None listed None listed None listed
Federal
Non-Insured Health Benefits Program F2 None listed None listed None listed None listed
Correctional Service Canada F2†† None listed None listed None listed None listed

*No specific criteria, but exclusion criteria stated: "Patients who are at high risk for non-compliance."

†However, prescriber could indicate that directly observed therapy was recommended; also, the patient consented (via signature) to understanding treatment adherence.

‡In year 1 (2015/16), only those with stage F3 or F4 fibrosis received reimbursement.

§Treated in year 1 if stage F3 or F4 fibrosis.

¶There were restrictions (e.g., active injection drug use) left to physician's discretion.

**Must be treated by a specialist off-island.

††Treatment prioritized to patients with stage F3 or F4 fibrosis; treatment for those with stage F0, F1 or F2 fibrosis was reviewed on a case-by-case basis.